

MINIMAL INVASIVE MONITORING OF VOLUME STATUS IN PATIENTS AFTER MAJOR ABDOMINAL SURGERY.

Published: 01-04-2010

Last updated: 04-05-2024

The primary objectives of this study consist of:1. To assess the accuracy of different pulse contour methods to measure CO compared to thermodilution CO measured with a PAC in major abdominal surgery patients.2. To assess the effect of propofol...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Gastrointestinal therapeutic procedures
Study type	Interventional

Summary

ID

NL-OMON39163

Source

ToetsingOnline

Brief title

-

Condition

- Gastrointestinal therapeutic procedures

Synonym

After major abdominal surgery

Research involving

Human

Sponsors and support

Primary sponsor: Leids Universitair Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Accuracy and precision, Hemodynamic monitoring, Minimal invasive, Propofol

Outcome measures

Primary outcome

Cardiac output measured with different pulse contour methods to measure CO compared to thermodilution CO measured with a PAC

Secondary outcome

-

Study description

Background summary

Determining volume status is important in critically-ill patients. Currently no gold-standard is available to accurately assess a patient's volume status and physicians use clinical signs and hemodynamic parameters (like cardiac output) to estimate volume status.

Currently, the Pulmonary Artery Catheter (PAC) is one of the standards to monitor major abdominal surgery patients. Its use, however, is related to complications upsetting its value in other subpopulations like septic patients. The primary aim of this study is to evaluate the use of less invasive techniques to determine cardiac output (with pulse contour) compared to thermodilution cardiac output measurement with a pulmonary artery catheter. If proven accurate less invasive techniques could replace the PAC in the perioperative monitoring of major abdominal surgery patients.

Study objective

The primary objectives of this study consist of:

1. To assess the accuracy of different pulse contour methods to measure CO compared to thermodilution CO measured with a PAC in major abdominal surgery patients.
 2. To assess the effect of propofol sedation and different hemodynamic challenges (PEEP increase, fluid challenge and passive leg raising) on the accuracy of the measurement of stroke volume variation (SVV), pulse pressure variation (PPV) and CO with different techniques.
 3. To assess the accuracy of a novel method to estimate mean systemic filling pressure (MSFP) compared to PAC measurement.
- 2 - MINIMAL INVASIVE MONITORING OF VOLUME STATUS IN PATIENTS AFTER MAJOR ABDOMINAL S ...

pressure against two validated methods.

Secondary objectives consist of:

1. To study the effect of propofol sedation on mean systemic filling pressure.
2. To study the effect of propofol on systemic, venous and arterial resistance.
3. To assess the value of dMAP, dCO, dCVP due to 30° PLR, 5 and 10 cm H₂O PEEP, 50 and 100 cc volume challenges to predict fluid loading responsiveness.
4. To assess the value of baseline CO, SVV, SPV, PPV and Pmsf to predict fluid loading responsiveness.

Study design

Prospective intervention and measurement study

Intervention

Hemodynamic measurements are performed during propofol infusion at a blood concentration of 4, 2 and 1 µg•mL⁻¹. Subsequently measurements are repeated prior to, 30 seconds after start and 2 minutes after returning to baseline conditions for 30° passive leg raising, PEEP +5 cmH₂O and PEEP +10cmH₂O. Finally, 500 mL of Voluven is administered in 50 mL bolus with intermediate measurements.

Study burden and risks

Propofol

Propofol is a GABAA agonist that is widely used as intravenous hypnotic for surgical anesthesia and for sedation during loco-regional anesthesia and at the ICU and PACU. We have experience with propofol in the PACU at the dose range studied and expect minimal hemodynamic side effects in the patients studied. These hemodynamic depressant effects of propofol are the result of peripheral vasodilatation and direct myocardial depression.

Pulmonary Artery Catheter

The standard of perioperative anesthetic care for patients scheduled for major abdominal surgery in the LUMC includes central venous catheterisation with or without pulmonary artery catheterisation. The insertion of a pulmonary artery catheter is left to the judgment of the attending anesthesiologist. The acquisition of venous access for both the central venous catheter and the PAC is associated with similar complications (id est arterial puncture, bleeding at the injection site, pneumothorax, air- or thrombo-embolism, arrhythmias, infections. Catheterization with a PAC may lead to more specific complications like mild tricuspid insufficiency, pulmonary artery rupture and pulmonary infarction. In a general ICU population the beneficial effects of the monitoring characteristics of the PAC is upset by its complications.. Several subpopulations, however, have shown to have improved survival due to the

monitoring capabilities of the PAC, for example high-risk cardiac surgery. Patients undergoing major abdominal surgery also have an indication for pulmonary artery catheterization for its use is associated with an improved outcome in patients after planned major surgery like those included in our study.

Contacts

Public

Leids Universitair Medisch Centrum

Albinusdreef 2
Leiden 2333 CL
NL

Scientific

Leids Universitair Medisch Centrum

Albinusdreef 2
Leiden 2333 CL
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- Scheduled for ventilation and sedation at the PACU after elective major abdominal surgery (i.e. any type of abdominal surgery with an indication for invasive monitoring with arterial and central venous catheters)
- Aged 18-65 years.
- Being able to give written informed consent prior to surgery

4 - MINIMAL INVASIVE MONITORING OF VOLUME STATUS IN PATIENTS AFTER MAJOR ABDOMINAL S ...

7-05-2025

Exclusion criteria

- Pregnancy
- Documented or suspected soybean protein and/or relevant drug allergy.
- Morbid obesity (BMI > 35)
- venous pressure (CVP) >18 mm Hg and/ or a cardiac index < 2.0 L•min⁻¹ or dependence on high dosages of inotropic drugs after admittance to the PACU
- Severe arrhythmias
- Renal insufficiency requiring dialysis
- Intra-cardiac shunts
- Symptomatic peripheral vascular disease
- Symptomatic pulmonary disease
- Clinically significant aortic aneurysm
- Significant valvular regurgitation
- Prior diagnosis of aberrant cardiovascular anatomy

Study design

Design

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 28-02-2011

Enrollment: 30

Type: Actual

Medical products/devices used

Product type: Medicine

Brand name: Propofol

Generic name: Propofol

Registration: Yes - NL intended use

Ethics review

Approved WMO	
Date:	01-04-2010
Application type:	First submission
Review commission:	METC Leids Universitair Medisch Centrum (Leiden)
Approved WMO	
Date:	24-08-2010
Application type:	First submission
Review commission:	METC Leids Universitair Medisch Centrum (Leiden)
Approved WMO	
Date:	13-10-2011
Application type:	Amendment
Review commission:	METC Leids Universitair Medisch Centrum (Leiden)
Approved WMO	
Date:	31-01-2013
Application type:	Amendment
Review commission:	METC Leids Universitair Medisch Centrum (Leiden)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2010-019073-15-NL
CCMO	NL31886.058.10